• Home
  • About
    • Who we are
    • Mission
    • Values
  • Science & Pipeline
  • Patients
  • Leadership
    • Leadership team
    • Board of Directors
    • Scientific Advisory Board
  • Investors & Media
    • Overview
    • Press Releases
    • Events
    • Publications / Presentations
    • Financial Information
    • Corporate Governance
    • Stock Information
    • Investor Resources
  • Careers
  • Contact Us
  • LinkedIn
  • Privacy
  • Terms of Use
Precision Oncology News: Kinnate Exiting Stealth Mode With Plans to Move Lead RAF Inhibitor Into Clinical Trials Next Year

Precision Oncology News: Kinnate Exiting Stealth Mode With Plans to Move Lead RAF Inhibitor Into Clinical Trials Next Year

by Kinnate | Jun 17, 2020 | Article

Precision Oncology News: Kinnate Exiting Stealth Mode With Plans to Move Lead RAF Inhibitor Into Clinical Trials Next Year June 16, 2020Most BRAF inhibitors that have been commercialized to date, or are being studied, go after BRAF V600 mutations, according to Kinnate...

Recent Posts

  • Kinnate Biopharma Appoints Dean J. Mitchell as Chairman of the Board
  • Kinnate Biopharma Closes $98 Million Series C Financing
  • Kinnate Biopharma Appoints Dr. Richard Williams as Chief Medical Officer
  • Precision Oncology News: Kinnate Exiting Stealth Mode With Plans to Move Lead RAF Inhibitor Into Clinical Trials Next Year
  • Kinnate Biopharma Appoints Nima Farzan as Chief Executive Officer

Recent Comments

    Archives

    • September 2020
    • August 2020
    • July 2020
    • June 2020
    • May 2020
    • December 2019
    • April 2018

    Categories

    • Article
    • News

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    LinkedIn
    Expanded Access
    Contact
    Privacy
    Terms of Use

    © 2023 Kinnate Biopharma.